Exploratory Profiling of ABC-Family Genes Identifies a Candidate Score in Pediatric Neuroblastoma

Abstract Background/Aim: High-risk pediatric neuroblastoma is characterized by frequent relapse and treatment resistance that are not fully explained by current risk stratification factors, including MYCN amplification. ATP-binding cassette (ABC) transporters are key mediators of multidrug resistance, but their clinical significance in pediatric neuroblastoma remains unclear. Materials and Methods: Expression of all 49 human ABC-family genes were systematically analyzed using the TARGET dataset. Associations with disease stage, MYCN amplification, and overall survival were evaluated using Kaplan–Meier analysis and multivariable Cox proportional hazards models adjusted for age and MYCN amplification. Key findings were further examined in an additional dataset (Versteeg-88), from which an exploratory ABC-family gene expression-based candidate score was derived, informed by both datasets. Results: Multiple ABC-family genes showed expression differences between stage 1 and stage 4 tumors and showed higher expression in MYCN-amplified tumors. In the multivariable Cox analysis, nine ABC-family genes showed nominal associations with overall survival after adjustment for age and MYCN amplification, although none remained significant after FDR correction. Exploratory evaluation in the Versteeg-88 dataset revealed concordant prognostic trends for genes meeting both exploratory criteria, from which an exploratory five-gene candidate score was derived. In exploratory analyses, the candidate score was associated with overall survival after adjustment for age and MYCN amplification, and this association was also observed in MYCN-non-amplified patients. Conclusion: We provide the first comprehensive landscape of ABC-family genes dysregulation in pediatric neuroblastoma. Our findings reveal a candidate score that was associated with overall survival after adjustment for MYCN amplification, thereby suggesting prognostic heterogeneity not explained by MYCN status alone. These findings offer an initial framework for understanding coordinated ABC-family gene expression and may inform future investigations of risk-refining approaches in pediatric neuroblastoma.

Authors

Institutions

Publication Details

Journal
Cancer Genomics & Proteomics
Published
2026-10-31
DOI
https://doi.org/10.21873/cgp.20623
Primary Topic
Neuroblastoma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploratory Profiling of ABC-Family Genes Identifies a Candidate Score in Pediatric Neuroblastoma

Kazunori Akimoto, Shingo Yamazaki, Hitomi Motomura
Cancer Genomics & Proteomics
Neuroblastoma Research and Treatments
article

Exploratory Profiling of ABC-Family Genes Identifies a Candidate Score in Pediatric Neuroblastoma

Kazunori Akimoto, Shingo Yamazaki, Hitomi Motomura
article en

Abstract

Abstract Background/Aim: High-risk pediatric neuroblastoma is characterized by frequent relapse and treatment resistance that are not fully explained by current risk stratification factors, including MYCN amplification. ATP-binding cassette (ABC) transporters are key mediators of multidrug resistance, but their clinical significance in pediatric neuroblastoma remains unclear. Materials and Methods: Expression of all 49 human ABC-family genes were systematically analyzed using the TARGET dataset. Associations with disease stage, MYCN amplification, and overall survival were evaluated using Kaplan–Meier analysis and multivariable Cox proportional hazards models adjusted for age and MYCN amplification. Key findings were further examined in an additional dataset (Versteeg-88), from which an exploratory ABC-family gene expression-based candidate score was derived, informed by both datasets. Results: Multiple ABC-family genes showed expression differences between stage 1 and stage 4 tumors and showed higher expression in MYCN-amplified tumors. In the multivariable Cox analysis, nine ABC-family genes showed nominal associations with overall survival after adjustment for age and MYCN amplification, although none remained significant after FDR correction. Exploratory evaluation in the Versteeg-88 dataset revealed concordant prognostic trends for genes meeting both exploratory criteria, from which an exploratory five-gene candidate score was derived. In exploratory analyses, the candidate score was associated with overall survival after adjustment for age and MYCN amplification, and this association was also observed in MYCN-non-amplified patients. Conclusion: We provide the first comprehensive landscape of ABC-family genes dysregulation in pediatric neuroblastoma. Our findings reveal a candidate score that was associated with overall survival after adjustment for MYCN amplification, thereby suggesting prognostic heterogeneity not explained by MYCN status alone. These findings offer an initial framework for understanding coordinated ABC-family gene expression and may inform future investigations of risk-refining approaches in pediatric neuroblastoma.

Cancer Genomics & ProteomicsVol. 23(6)
Tokyo University of Pharmacy and Life Sciences (JP), Chiba University (JP), Tokyo University of Science (JP), Chiba University Hospital (JP), Research Institute for Science and Technology, Tokyo University of Science (JP)
Openalex Percentile: Top 13%
Neuroblastoma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon